Schonfeld Strategic Advisors LLC Regenxbio Inc. Transaction History

Schonfeld Strategic Advisors LLC

$14 Billion
Q1 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 183,795 shares of RGNX stock, worth $1.95 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

183,795

Holding current value

$1.95 Million

% of portfolio

0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $2.24 Million - $4.52 Million	183,795 New	183,795 $3.87 Million
Q3 2022 Nov 14, 2022	BUY	$22.29 - $35.04 $168,913 - $265,533	7,578 New	7,578 $200,000
Q4 2019 Feb 14, 2020	SELL	$34.54 - $44.87 $376,486 - $489,083	-10,900 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$31.84 - $50.88 $999,776 - $1.6 Million	-31,400 Reduced 74.23%	10,900 $387,000
Q2 2019 Aug 14, 2019	SELL	$42.0 - $59.29 $1.97 Million - $2.77 Million	-46,800 Reduced 52.53%	42,300 $2.17 Million

Q1 2019 May 15, 2019	BUY	$40.82 - $62.45 $3.64 Million - $5.56 Million	89,100 New	89,100 $5.11 Million
Q4 2018 Feb 14, 2019	SELL	$39.11 - $75.15 $1.01 Million - $1.93 Million	-25,700 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$65.0 - $82.15 $5.47 Million - $6.92 Million	-84,200 Reduced 76.62%	25,700 $1.94 Million
Q2 2018 Aug 14, 2018	BUY	$27.2 - $74.35 $1.63 Million - $4.45 Million	59,900 Added 119.8%	109,900 $7.89 Million
Q1 2018 May 15, 2018	SELL	$24.05 - $37.5 $2.61 Million - $4.08 Million	-108,687 Reduced 68.49%	50,000 $1.49 Million
Q4 2017 Feb 14, 2018	BUY	$26.0 - $34.6 $482,742 - $642,418	18,567 Added 13.25%	158,687 $5.28 Million
Q3 2017 Nov 14, 2017	BUY	$18.0 - $32.95 $2.52 Million - $4.62 Million	140,120	140,120 $4.62 Million

Others Institutions Holding RGNX

# of Institutions

193

Shares Held

42M

Call Options Held

80.6K

Put Options Held

55.2K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $458M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Regenxbio Inc. Transaction History